LitAlert ~~ GeneLit.com

    • Co-occurrence of germline BRCA1 and CDH1 pathogenic variants.
    • Villy MC, Mouret-Fourme E, Golmard L, Becette V, Callet N, Marx G, Colas C, Lamarque D, Rouleau E, Stoppa-Lyonnet D.
    • J Med Genet. 2020 Jun 23:jmedgenet-2020-106972. doi: 10.1136/jmedgenet-2020-106972. Epub ahead of print.
    • Case report
    • Multiple primary tumors: a case report and review of the literature.
    • Zhao Z, Sun K, Yan T, Wei R, Guo W.
    • BMC Musculoskelet Disord. 2020 Jun 22;21(1):394. doi: 10.1186/s12891-020-03426-8.
    • Breast cancer risk prediction models and subsequent tumor characteristics.
    • Miller EA, Pinsky PF, Heckman-Stoddard BM, Minasian LM.
    • Breast Cancer. 2020 Jul;27(4):662-669. doi: 10.1007/s12282-020-01060-9. Epub 2020 Feb 13.
    • Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    • Lee EK, Matulonis UA.
    • Expert Opin Emerg Drugs. 2020 Jun 22:1-23. doi: 10.1080/14728214.2020.1773791. Epub ahead of print.
    • Review
    • Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
    • Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS.
    • J Clin Oncol. 2020 Jun 22:JCO1902404. doi: 10.1200/JCO.19.02404. Epub ahead of print.
    • The forefront of ovarian cancer therapy: update on PARP inhibitors.
    • Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S.
    • Ann Oncol. 2020 Jun 19:S0923-7534(20)39891-4. doi: 10.1016/j.annonc.2020.06.004. Epub ahead of print.
    • Review